Lupus & antiphospholipid syndrome
Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial Emulation
Authors' conclusion
In this emulated clinical trial, treatment with SGLT2i, compared to DPP4i therapy, was associated with significantly reduced risks of several cardiorenal complications among patients with both SLE and T2D.
Study context
- Population
- Patients with both systemic lupus erythematosus (SLE) and comorbid type 2 diabetes, insurance-based cohort in the United StatesMean follow-up 753.1 (±479.2) days
- Participants
- 2,165 vs 2,165
- Exposure
- SGLT2i vs DPP4i
- SGLT2in = 2,165
- DPP4in = 2,165reference
- Outcome
- Primary prevention of cardiovascular, renal, and other clinical outcomes
Methodological detailspopulation-based cohort study, propensity-score matched, insurance-based cohort, Cox models
- Population-based cohort study
- Propensity-score matched
- Insurance-based cohort
- Cox models
Main finding
As reported in the abstract
mean 753.1 (±479.2) days
SGLT2i vs DPP4iHazard ratio (95% CI)
Acute kidney injury
0.49(0.39–0.63)
CKD
0.61(0.50–0.76)
End-stage renal disease
0.40(0.20–0.80)
HF
0.72(0.56–0.92)
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| ED visits | 0.90 (0.82–0.99) | |
| 0.512Hazard ratio (log scale) |
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Severe sepsis | 0.61 (0.39–0.94) | |
| 0.20.5125Hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial Emulation. Arthritis Rheumatol. Published 5 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →